Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cognitive functioning during sunitinib or sorafenib treatment
NL-OMON32837Phase 4Withdrawn
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sunitinib and sorafenib in renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST) (4 arms), sponsored by Radboud University Medical Center. Primary endpoints: Neuropsychological test results, Laboratory test results and 6 more. Planned start Mar 2009; status: withdrawn.
02
Drugs
sunitinibsorafenib
03
Conditions
renal cell carcinoma (RCC)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON32837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32837.